The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens

Human Pathology

Volumn 30, Issue 12, 1999, Pages 1405-1411

  Costes, Valérie ^a   Magen, Valérie ^b   Legouffe, Eric ^b   Durand, Luc ^b   Baldet, Pierre ^b   Rossi, Jean François ^b   Klein, Bernard ^b   Brochier, Jean ^b  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b NONE

Author keywords

B cell lymphoma; Hodgkin's disease; Immunohistochemistry; Mi15; Multiple myeloma; Plasma cells; Syndecan 1

Indexed keywords

CD15 ANTIGEN; CD20 ANTIGEN; CD30 ANTIGEN; CELL MARKER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MI 15; PARAFFIN; SYNDECAN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CELL COUNT; CONTROLLED STUDY; EMBEDDING; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PLASMACYTOMA; PLASMACYTOSIS; REED STERNBERG CELL; T CELL LYMPHOMA;

EID: 0033450858     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(99)90160-0     Document Type: Article

References (37)

1. Anderson KC, Park E, Bates M, et al: Antigens on human plasma cells identified by monoclonal antibodies. J Immunol 130:1132-1138, 1983
2. Anderson KC, Bates M, Slaughenhoupt B, et al: A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. J Immunol 132:3172-3179, 1984
3. Gondoroff N, Katzman J, Garton J, et al: A monoclonal antibody reactive with a subset of human plasma cells. Br J Haematol 62:619-630, 1986
4. Tazzari P, Gobbi M, Dinota A, et al: Normal and neoplasic plasma cell membrane phenotype: Studies with new monoclonal antibodies. Clin Exp Immunol 70:192-200, 1987
5. Tong A, Lee F, Stone M: Characterization of a monoclonal antibody having selective reactivity with normal and neoplastic plasma cells. Blood 69:238-245, 1987
6. Huang N, Kawano M, Harada Y, et al: Heterogeneous expression of a novel MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. Blood 82:3721-3729, 1993
7. Goto T, Kennel S, Abe M, et al: A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84:1922-1930, 1994
8. Turley H, Jones M, Erber W, et al: A new monoclonal antibody for detecting plasma cell differenciation in routine sections. J Clin Pathol 47:418-422, 1994
9. Wijdenes J, Wooijs W, Clément C, et al: A plasmocyte selective monoclonal antibody (BB4) recognizes syndecan-1. Br J Haematol 94:318-323, 1996
10. Horvathova M, Gaillard JP, Liautard J, et al: Identification of novel and specific antigens of human plasma cells by mAB, in Leucocyte Typing V. London, England, Oxford University Press, 1995, pp 713-717
11. Wijdenes J, Clément C, Klein B, et al: CD138 cluster report, in Kishimoto et al (eds) : Leucocyte Typing VI. New York, NY, Garland, 1997, pp 249-252
12. Kaukonen J, Alanen-Kurki L, Jalkanen M, et al: The mapping and visual ordering of the syndecan-1 and N-myc genes near the telomeric region of chromosome 2p. Hum Genet 99:295-297, 1997
13. Elenius K, Jalkanen M: Function of the syndecans, a family of cell surface proteoglycans. J Cell Sci 107:2975-2982, 1994
14. Kiefer M, Stephans J, Crawford K, et al: Ligand-affinity cloning and structure of a cell surface heparan sulfate proteoglycan that binds basic fibroblast growth factor. Proc Natl Acad Sci 87:6985-6990, 1990
15. Yayon A, Klagsbrun M, Esko J, et al: Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64:841-891, 1991
16. Bernfield M, Kokenyesi R, Kato M, et al: Biology of the syndecans: A family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 8:365-393, 1992
17. Vainio S, Jalkanen M, Vaahtokari A, et al: Expression of syndecan gene is induced early, is transient, and correlates with changes in mesenchymal cell proliferation during tooth organogenesis. Dev Biol 147:322-329, 1991
18. Kato M, Saunders S, Nguyen H, et al: Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 6:559-576, 1995
19. Jiang R, Kato M, Bernfield M, et al: Expression of syndecan-1 changes during the differentiation of visceral and parital endoderm from murine F9 teratocarcinoma cells. Differentiation 59:225-233, 1995
20. Sanderson RD, Laor P, Bernfield M: B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1:27-35, 1989
21. Portier M, Rajzbaum G, Zhang X, et al: In vitro interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 21:1759-1785, 1991
22. Sun RX, Lu ZY, Widjness J, et al: Large scale and clinical grade purification of syndecan-1 malignant plasma cells. J Immunol Methods 205:73-79, 1997
23. Zhang XG, Gaillard JP, Robillard N, et al: Reproductible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83:3654-3663, 1994
24. Malpas J, Bergsagel D, Kyle R: Clinical presentation and diagnostic of multiple myeloma, in Myeloma: Biology and Management. New York, NY, Oxford University Press, 1995, pp 173-195
25. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Study Group. Blood 84:1361-1392, 1994
26. Cordell J, Falini B, Erber W, et al: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219-225, 1984
27. Bartl R, Frisch B: Bone marrow biopsy and aspiration for diagnosis of multiple myeloma, in Myeloma: Biology and Management. New York, NY, Oxford University Press, 1995, pp 89-121
28. Ridley R, Xiao H, Hata H, et al: Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 81:767-774, 1993
29. Dhodapkar MV, Abe E, Theus A, et al: Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth and bone cell differentiation. Blood 91:2679-2688, 1998
30. Jourdan M, Ferlin M, Legouffe E, et al: The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 100:637-646, 1998
31. Carbone A, Glohgini A, Gattei V, et al: Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood 89:3787-3794, 1997
32. Carbone A, Gloghini A, Gaidano G, et al: Expression status of Bcl-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood 92:2220-2228, 1998
33. Carbone A, Gaidano G, Gloghini A, et al: Differential expression of bcl-6, CD138/syndecan-1, and Epstein-Barr virus encoded latent membrane protein-1 identifies distinct histogenetic subset of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 3:747-755, 1998
34. Nackaerts K, Verbeken E, Deneffe G, et al: Heparan sulfate proteoglycan expression in human lung-cancer cells. Int J Cancer 20:335-345, 1997
35. Elenius K, Vainio S, Laato M: Induced expression of syndecan in healing wounds. J Cell Biol 114:585-595, 1991
36. Inki P, Joensuu H, Grenman R, et al: Association between syndecan-1 expression and clinical outcome of the head and neck. Br J Cancer 70:319-323, 1994
37. Pulkkinen JO, Penttinen M, Jalkanen M, et al: Syndecan-1: A new prognostic marker in laryngeal cancer. Acta Otolaryngol 117:312-315, 1997